

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-34 (cancelled).

35 (new). An isolated antigenic *Porphorymonas gingivalis* polypeptide, the polypeptide comprising:

an amino acid sequence of SEQ ID NO: 424; or

an amino acid sequence at least 85% identical to the amino acid sequence of SEQ ID NO: 424; or

at least 40 amino acids having a contiguous sequence of at least 40 amino acids identical to a contiguous amino acid sequence comprising SEQ ID NO: 424.

36 (new). A polypeptide as claimed in claim 35 in which the amino acid sequence is at least 95% identical to the amino acid sequence of SEQ ID NO: 424.

37 (new). A polypeptide as claimed in claim 35 in which the polypeptide comprises the amino acid sequence of SEQ ID NO: 424.

38 (new). A polypeptide as claimed in claim 35 in which the polypeptide comprises an amino acid sequence at least 85% identical to the amino acid sequence of SEQ ID NO: 424.

39 (new). A polypeptide as claimed in claim 38 in which the polypeptide comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 424.

40 (new). A polypeptide as claimed in claim 35 in which the polypeptide comprises at least 40 amino acids having a contiguous sequence of at least 40 amino acids identical to the contiguous amino acid sequence of SEQ ID NO: 424.

41 (new). An isolated antigenic *Porphyromonas gingivalis* polypeptide, the polypeptide comprising an amino acid sequence of SEQ ID NO: 424 less the leader sequence set out in Table 3.

42 (new). A composition for use in raising an immune response directed against *P. gingivalis* in a subject, the composition comprising an effective amount of the polypeptide as claimed in claim 35 and a pharmaceutically acceptable carrier.

43 (new). A composition as claimed in claim 42 in which the pharmaceutically acceptable carrier is an adjuvant.